Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors are game-changers in the treatment of T2DM and are currently promoted by major clinical guidelines among potential first-line pharmacological options after failure/intolerance to metformin, especially in individuals with an atherosclerotic cardiovascular disease phenotype (GLP-1 RAs) [174]
It's important to discuss your long-term goals with our team to create a plan that works for you
Doing so may result in contamination, infections, or other serious health complications
Statements on this site have not been evaluated by the U.S
They can provide personalized advice, monitor progress, help manage side effects, ensure nutritional adequacy, and offer crucial support and accountability
The current production lot's COA is published on the Lab Results page